Aims-To determine the prevalence of cells secreting interleukin-4 (IL-4) in the gut mucosa of children with chronic inflammatory bowel disease. Methods-Mononuclear cells were isolated from intestinal biopsy specimens from control children (n = 10) and children with active inflammatory bowel disease (Crohn's disease n = 15, ulcerative colitis n = 9, indeterminate colitis n = 3). Spontaneous IL-4 production was then measured by SPOT-enzyme linked immunosorbant assay (ELISA) using a pair of non-competing anti-IL-4 monoclonal antibodies. The percentage of T cells in the isolated cells was also determined and the prevalence of IL-4 secreting cells calculated per 10 000 T cells.
There is increasing evidence that T cell immunity has a primary role in the pathogenesis of the chronic granulomatous inflammation in the gut mucosa of patients with Crohn's disease. Use of immunohistochemistry, polymerase chain reaction (PCR), northern blots, measurement of T cell derived lymphokines in serum, and functional assays of lymphokine release shows that there seems to be an ongoing T cell response in the mucosa in Crohn's disease that is not detectable in ulcerative colitis.' 5 The antigens driving this response are not known. Animal models of Crohn's disease rely on the generation of T cell responses in the gut wall.6 8 Studies to date on T cell lymphokine release in the mucosa in Crohn's disease have concentrated on the measurement of interleukin-2 (IL-2) and interferon-y. It is becoming increasingly clear, however, that these cytokines are produced mainly by Thi-type helper T cells and that activated Th2-type helper T cells can produce other cytokines such as or IL-5.9 '°Thus, the absence of IL-2 and interferon-y secreting cells in ulcerative colitis may not be due to the absence of T cell activation, but to the T cells releasing other cytokines (a Th2 response).
To address this question, we isolated cells from the intestinal mucosa of children with Crohn's disease, ulcerative colitis, or controls and determined whether they were secreting IL-4, using the well established enzyme linked immunosorbent SPOT (ELISPOT) assay.' Methods Clinical details of the patients are shown in the table. Biopsy specimens were obtained from 37 patients. Children with inflammatory bowel disease were all in the active phase of the disease. All children underwent colonoscopy because of known inflammatory bowel disease in relapse or for initial investigation (table) . Of the patients with Crohn's disease receiving treatment, elemental diet had been administered for eight weeks, cyclosporin A for eight weeks, prednisolone only between six and 10 weeks, prednisolone and mesalazine between four and 20 weeks and mesalazine only for two weeks before endoscopy.
Patients with ulcerative colitis receiving treatment before endoscopy received either cyclosporin for eight weeks, prednisolone only for eight to 10 weeks, prednisolone and mesalazine for four to eight weeks, or mesalazine only for six weeks. The two patients with indeterminate colitis receiving treatment received either prednisolone for eight weeks or prednisolone and mesalazine for six weeks before endoscopic examination. Multiple biopsy specimens were taken from the terminal ileum and colon for histopathological analysis. Two biopsy specimens were also taken from a site of active inflammation (taking care to avoid ulcers) in children with endoscopically visible disease. Children with no endoscopic disease had biopsy specimens taken from the transverse colon or caecum.
The degree of inflammation in two biopsy specimens taken adjacent to those taken for measurement of IL-4 secretion was graded blind as mild, moderate, or severe by an independent histopathologist using the criteria described elsewhere. 12 All biopsy specimens for histological assessment were assigned an overall inflammation score. Separate scores were given for small and large bowel as appropriate. The score ranged from 0-3 (where 0 was normal, 1 was mild inflammation, 2 was moderate inflammation, and 3 was severely inflamed), according to the presence of ulceration, acute and chronic inflammation, crypt 
Results
There was a slightly higher percentage of T cells in the cell suspensions isolated from children with inflammatory bowel disease than control children, but it did not reach significance because of the wide ranges (fig 1) .
When the prevalence of IL-4 secreting cells per 10 000 T cells was determined in control children, a mean of 15 cells per 104 T cells were secreting IL-4 (range two to 57). This was significantly reduced to around 5 cells per 104 T cells in children with ulcerative colitis or Crohn's disease, although again there was a wide variation between individual patients. Two of three children with indeterminate colitis also had levels of 1 and 2 IL-4 secreting cells per 104 T cells (fig 2) .
There were enough children with active Crohn's disease to determine whether the reduction was related to steroid use or to the histological severity of the lesion. There was no difference in the prevalence of IL-4 secreting cells between children treated with steroids or those treated with enteral nutrition or no treatment (fig 3) . The subgroup of four children with untreated Crohn's disease had low numbers of IL-4 secreting cells (1,3,3,8 per 10 000 T cells). A single child treated with mesalazine alone also had low numbers of IL-4 secreting cells (2 per 10 000 T cells). The children treated with steroids (n = 7) fell into two distinct subgroups, four with low levels (1,1,2,4 per 10 000 T cells) and three with high levels (8, 13, 17) . Although the numbers in each group are small, there was no correlation with histological severity of disease, most patients having less than 5 IL-4 secreting cells per 10 000 T cells (fig 4) .
Because of small patient numbers, it was impossible to determine whether there were differences between patients treated with steroids alone, steroids plus mesalazine, or cyclosporin A.
Blood lymphocytes from three healthy donors were also studied and the prevalence of spontaneous IL-4 secreting cells was very low (0l2-0l3 cells per 10 000 T cells).
Discussion
This study was carried out for two main reasons. First to determine whether in ulcerative colitis T cells were producing a Th2-type cytokine, such as IL-4, as we had already shown that, in contrast to Crohn's disease, IL-2 and interferon-y production was low in ulcerative colitis.3 The answer to this question is clear. There is no evidence for increased IL-4 production in ulcerative colitis nor in Crohn's disease, thus further substantiating our notion that Crohn's disease is due to a Thl-type T cell response in the gut mucosa. The second question was whether IL-4 is produced in the gut during inflammation, regard- '6 this does not seem to be a major pathway in inflammatory bowel disease.
The major finding in this paper is that numbers of IL-4 secreting cells were reduced in the intestinal mucosa in Crohn's disease, ulcerative colitis, and in two of three patients 
